Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

David R Corey

Showing results (1-10 of 159) with videos related to

Pageof 16
Sort By:
Methods in Molecular Biology (Clifton, N.J.)|June 16, 2004
Synthesis of oligonucleotide-peptide and oligonucleotide-protein conjugatesDavid R Corey
The Journal of Clinical Investigation|December 7, 2007
Chemical modification: the key to clinical application of RNA interference?David R Corey
JAMA Neurology|November 2, 2016
Doubts About Therapy for Neurological Diseases With Antisense Oligonucleotides-ReplyDavid R Corey
Nucleic Acid Therapeutics|November 21, 2024
It is Time to Revisit miRNA TherapeuticsDavid R Corey
JAMA Neurology|August 2, 2016
Synthetic Nucleic Acids and Treatment of Neurological DiseasesDavid R Corey
Oncogene|February 19, 2002
Telomerase inhibition, oligonucleotides, and clinical trialsDavid R Corey
Nature Neuroscience|February 14, 2017
Nusinersen, an antisense oligonucleotide drug for spinal muscular atrophyDavid R Corey
Idrugs : the Investigational Drugs Journal|March 9, 2006
EuroTIDES 2005--Sixth Annual IBC Conference. Oligonucleotide, RNAi and peptides for the drug development and manufacturing industryDavid R Corey
Advances in Experimental Medicine and Biology|June 23, 2017
RNA-Mediated Gene Activation: Identifying a Candidate RNA for Preclinical DevelopmentDavid R Corey
Chemistry & Biology|August 30, 2005
Calcium liberates PNAs from endosomesDavid R Corey
Pageof 16

Showing results (1-10 of 159) with videos related to

Sort By:
Pageof 16
Methods in Molecular Biology (Clifton, N.J.)|June 16, 2004
Synthesis of oligonucleotide-peptide and oligonucleotide-protein conjugatesDavid R Corey
The Journal of Clinical Investigation|December 7, 2007
Chemical modification: the key to clinical application of RNA interference?David R Corey
JAMA Neurology|November 2, 2016
Doubts About Therapy for Neurological Diseases With Antisense Oligonucleotides-ReplyDavid R Corey
Nucleic Acid Therapeutics|November 21, 2024
It is Time to Revisit miRNA TherapeuticsDavid R Corey
JAMA Neurology|August 2, 2016
Synthetic Nucleic Acids and Treatment of Neurological DiseasesDavid R Corey
Oncogene|February 19, 2002
Telomerase inhibition, oligonucleotides, and clinical trialsDavid R Corey
Nature Neuroscience|February 14, 2017
Nusinersen, an antisense oligonucleotide drug for spinal muscular atrophyDavid R Corey
Idrugs : the Investigational Drugs Journal|March 9, 2006
EuroTIDES 2005--Sixth Annual IBC Conference. Oligonucleotide, RNAi and peptides for the drug development and manufacturing industryDavid R Corey
Advances in Experimental Medicine and Biology|June 23, 2017
RNA-Mediated Gene Activation: Identifying a Candidate RNA for Preclinical DevelopmentDavid R Corey
Chemistry & Biology|August 30, 2005
Calcium liberates PNAs from endosomesDavid R Corey
Pageof 16